Na fa'ailoa mai e le Phio Pharmaceuticals Corp. i le aso nei ua tatalaina le lesitalaina o tagata ma'i i le Vaega 1b fa'ata'ita'iga a le PH-762 mo togafitiga o le ma'i ma'i.
"Matou te fiafia e faʻalautele le matou faʻataʻitaʻiga muamua-i-tagata mo la matou polokalame taʻitaʻia, PH-762, e togafitia ai maʻi mamaʻi. O le amataga o lenei su'esu'ega fa'afoma'i ua fa'ailogaina ai se fa'ailoga taua mo Phio ma le matou INTASYL therapeutic platform," o le tala lea a Dr. Gerrit Dispersyn, Peresetene ma le Pule Sili o Phio. "O se suʻesuʻega taua lea mo tagata mamaʻi e maua i le melanoma maualuga, talu ai i le taimi nei, e leai ni togafitiga faʻapitoa e faʻamaonia mo nei gasegase. E le gata i lea, o le polokalame falemaʻi mo PH-762 e togafitia ai le melanoma o loʻo lagolagoina e se seti malosi o faʻamatalaga faʻapitoa na gaosia i nai tausaga ua tuanaʻi. O nei faʻamaumauga o loʻo faʻaalia ai o togafitiga faʻapitonuʻu o le PH-762 e taofia ai e le gata i le tuputupu aʻe o le tuma i le lotoifale, ae faʻaalia ai foi se aafiaga abscopal poʻo le faʻaogaina o le tali atu i le tino, e leʻi togafitia.
O le Vaega 1b suʻesuʻega, lea o loʻo faʻatautaia i le Gustave Roussy Institute, o se tasi o nofoaga sili ona tele o le kanesa i Europa, o le a iloiloina le saogalemu, tolerability, pharmacokinetics ma le anti-tumor gaioiga o le PH-762 i se tulaga neoadjuvant i mataupu e maualuga le melanoma. . Ole su'esu'ega fa'afoma'i ole a fa'aalia ai le fa'atuputeleina ole fua ole PH-762 monotherapy ma ua mamanuina e fa'ataga ai se su'esu'ega fa'ata'ita'iga ole fua ole Vaega 2 fautuaina. Ole su'ega muamua lea ile falema'i ile PH-762.
PH-762, fa'agaoioi sela puipuia e iloa lelei ma tapeina sela o le kanesa. E faia e ala i le faʻaitiitia o le faʻaaliga o le PD-1, o se faʻataʻitaʻiga faʻamaonia mo le immunotherapy. O le PD-1 e fa'aalia e sela T ma puipuia ai mai le tapeina o sela o le kanesa. A faʻaitiitia e le PH-762 le faʻaaliga PD-1, o le " taofi" i luga o le puipuiga o le tino e faʻamalolo ma faʻagaoioia le T cell e tape ai sela o le kanesa. O le PH-762 o loʻo faʻatulagaina e avea o se vailaʻau tutoʻatasi faʻatasi ma le pulega faʻapitonuʻu i se tuma. E le gata i lea, o loʻo faʻatupuina foi e avea o se vaega taua o le immunotherapy telefoni feaveaʻi, aemaise lava e faʻaleleia atili ai le gafatia o le fasioti tagata tumo o le faʻaaogaina o le tumo infiltrating lymphocyte (TIL) togafitiga.
OA MEA E AVEA MAI LENEI TUSI:
- The Phase 1b study, which is being conducted at the Gustave Roussy Institute, one of the largest cancer centers in Europe, will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.
- The clinical study will feature a dose escalation of PH-762 monotherapy and is designed to allow for a data driven evaluation of the recommended Phase 2 dose.
- In addition, the clinical program for PH-762 to treat melanoma is supported by a robust set of preclinical data generated over the past several years.
